Objectives: Several models have been developed to predict mortality in ischaemic stroke. We aimed to evaluate systematically the performance of published stroke prognostic scores.
Introduction
Strokes are one of the leading causes of mortality and morbidity world-wide. Annually, 15 million people worldwide suffer a stroke; of these, 5 million die and another 5 million are left permanently disabled. (1) Mortality from stroke is particularly prominent in the first 30 days following the event. (2) A number of studies in recent years have focused on deriving and validating prognostic scores for early mortality after ischaemic stroke in the acute setting, (3) (4) (5) with one study demonstrating that prognostic scoring had substantially greater predictive accuracy than physicians' judgments. (6) Availability of reliable prognostic tools could improve clinical care, guide shared decision-making and enhance communication between clinicians and patients. The possibility of matching patients according to prognostic score also enables stroke physicians to do comparative evaluations of different models of stroke care, whether as part of quality improvement projects or clinical trials. However, absence of uniformly accepted prognostic tool amongst the myriad of options is an important barrier.
We are not aware of any recent meta-analyses of stroke prognosis tools, but there has been a previous systematic review published by Counsell in 2001. (7) This systematic review critically appraised 83 separate prognostic models and identified serious deficiencies in the statistical validity, generalizability and validity of the evidence at that time. There has since emerged a plethora of publications reporting on different stroke prognosis scores. (4, 5, (8) (9) (10) Hence, we aimed to synthesize recent evidence on prognostic models in patients presenting acutely with ischaemic strokes, and to assess comparative performance of different scores so that clinicians and researchers can make informed decisions on use of such tools.
Methods

Eligibility criteria
We selected studies that used clinical variables (or groups of variables) in multivariate clinical prognostic models for overall mortality (< 6 months) in adult patients presenting with stroke.
Eligible studies had to have a majority of participants with ischaemic stroke, with reporting of test performance through sensitivity/ specificity or area under receiver operating characteristic (AUC) or c-statistic. As our main aim was to produce a synthesis of up to date evidence, we restricted our selection to studies published from 2003 onwards.
We excluded studies that were designed solely to correlate mortality with laboratory (e.g. albumin, white cell count, copeptin, etc.) or radiological variables (such as size of lesion). We did not consider studies that reported only on functional outcomes, or were based only on patients requiring intensive care. As our main focus was on stroke patients presenting to healthcare facilities, we excluded studies that focused on mortality in specific subsets of patients e.g. following a particular intervention (i.e. after thrombolysis or thrombectomy), or those that specifically examined stroke in a particular brain area (e.g. thalamic, or basilar).
Search strategy
We searched MEDLINE and EMBASE (OvidSP interface, February 2014) using the search terms listed in Supplementary Material 1, without any language restriction. We also checked the bibliographies of included studies for any potentially suitable studies.
Study selection and data extraction
We allocated study screening and data extraction to pairs of reviewers (KM, CSK, KP, AM, YKL) who independently scanned all titles and abstracts for potentially relevant articles, before proceeding to obtain full text versions for further checking. Any uncertainties and discrepancies were resolved through discussion and with a third reviewer. We also contacted authors if there were any areas that required further clarification.
We used a standardized form for data collection which included details on the setting, date of study, country of origin, selection criteria, participant characteristics, and outcome measures.
Assessment of Study Validity
For the assessment of study validity, pairs of reviewers independently checked whether there was clear reporting of neuroimaging, time of patient assessment, missing or incomplete data, and treatment protocols.
Data analysis
We focused on the Area under the Receiver Operating Curve (AUC) or c-statistic (which are equivalent measures of the discriminant ability for binary outcomes). (11) Here, the discriminant ability reflects how well the model separates patients who die during follow-up as opposed to those who survive. For studies that reported on both derivation and validation components, we chose to analyze data relating to the validation portion. If different mortality time-points were reported in a single study, we focused on 30-day as the first choice, inpatient mortality as the second choice, and where neither were available, we accepted a time point (< 6 months) for analysis. If a number of AUC values were available for a particular prognostic tool, we calculated a weighted pooled average using random effects inverse variance meta-analysis. If the AUCs were listed without standard errors, we imputed these values from the 95% confidence intervals or through Hanley's method. (12) We assessed heterogeneity through the I 2 statistic and visual inspection of the Forest plots. 
Results
We included 18 relevant studies from 2374 hits that were retrieved through the electronic database search. (3-5, 8-10, 14-25) The flow chart of study selection is shown in Figure 1 .
Characteristics and results of the included studies are shown in Supplementary Table A1, while assessment of study validity is reported in Supplementary Table A2 .
The included studies had a total of 163240 participants (sample sizes from 75 -109995), with mean age 71 years, while 54% of the participants were male. There were 10 multi-centre studies that recruited patients from more than two healthcare sites. (3-5, 8-10, 18, 19, 22, 25) Geographical locations were diverse, and included North America, Europe, Egypt and Asia. All the studies evaluated score validation, except for three that were mainly derivation studies. (8,
19, 23)
Validity assessment
As the majority of studies were retrospective in design, or posthoc analyses of prospectively collected clinical data, we were seldom able to judge if the prognostic variables were collected early in the course of the presentation. Treatment pathways were seldom reported, with only three studies explicitly stating that participants received similar care. (14, 18, 19) We recorded more complete reporting of the modality used in neuroimaging (12 studies), as well as amount of missing data (10 studies). (Supplementary Table A2 ) In view of the lack of detail in methodological reporting, we have not attempted to categorize studies into either a high or low quality subgroup. The AUCs from individual studies, as well as pooled mean AUC across studies (and heterogeneity statistic) are shown in Figure 2 . A summary of the information required in the calculation of each prognostic tool is available in Supplementary Table 3 . 
Quantitative comparison of AUC
NIHSS
The performance of the NIHSS was reported in three cohorts with a total of 50864 participants from India (30-day mortality), North America and China (both focusing on inpatient mortality). 
Essen Stroke Risk Score (ESRS)
The performance of the ESRS in predicting 90-day or inpatient mortality was reported in two cohorts with a total of 7570 participants from multiple centres. (18, 20) Point estimates of the AUC were identical in both studies, and yielded a weighted pooled average of 0.71 (0.69 -0.72).
GWTG, with or without NIHSS
There were two studies reporting on the performance of the GWTG score on its own for predicting inpatient mortality. 
Prognostic scores with AUC from single cohorts not included in comparative meta-analysis
We identified only one study reporting on the prognostic value of the GCS. This study recruited 
Studies not suitable for quantitative AUC analysis
Three studies reported only on sensitivity and specificity of the prognostic model. 
Discussion
Although the prediction of mortality in ischaemic stroke is complex, our review has identified several promising developments with moderate to good performance that can help clinicians and researchers decide which score to use. One of the frontrunners is the iSCORE. This prognostic model has the largest number of validation studies within our systematic review and has been tested in different countries (Canada, France, Greece and Korea) with consistently good results.
(4, 14, 16, 22) An important barrier to the use of iSCORE by non-specialists is the need to calculate a neurological subscale, either the Canadian Neurological Scale (CNS) or NIHSS score beforehand. This additional step is potentially laborious and may require additional training.
However, it is possible to calculate the iSCORE online [http://www.sorcan.ca/iscore/] or via a mobile application that has some guidance on the CNS score, and there appears to be less of a problem with missing data items with the CNS than with NIHSS. (26) A further point to consider in relation to the iSCORE is that if the NIHSS score is already available, then that alone may be sufficient to provide prognostic accuracy similar to that of the iSCORE. We found that the NIHSS score has been reported in three cohorts from India, North
America and China with a very similar weighted pooled average AUC (good predictive accuracy) to the iSCORE. Nevertheless, we also recognize that NIHSS scoring can be complex for non-specialists or difficult to obtain (missing in 60% of participants from a North American cohort), (5)and there are problems with inter-rater reliability. (26) Based on the pooled average AUC, we would consider the GWTG and SOAR scores to have moderate performance in predicting mortality after ischaemic stroke; the major advantage being ease of use by non-specialists because neither of GWTG nor SOAR requires use of neurological severity subscales such as the NIHSS. However, each of these scores has been evaluated in only two studies and we feel that there is a need to validate these further; a direct comparison with the iScore would be desirable. It is also important to note that one of the elements needed for the SOAR score is the Oxford Community Stroke Project classification (OCSP), which requires greater depth of knowledge, and may not always correlate well with findings on brain imaging.
(27) There are issues arising from variation in inter-rater reliability with the OCSP and modified Rankin score (both of which are components of SOAR), (28) thus potentially leading to inconsistent estimates in the final score . An advantage of the GWTG score is that is does not require such pre-knowledge (of the NIHSS or OCSP for example) in order to complete it.
However, two studies that directly compared GWTG with NIHSS found that NIHSS offered greater discriminant ability than GWTG alone. (5, 25)
The PLAN score also has a similar weighted pooled average AUC (good predictive accuracy) compared to the iSCORE and NIHSS, however, we found only one study reporting it. (9) In this study, the performance of PLAN in patients who received thrombolysis was weaker, for reasons which are as yet unclear. It does appear to be promising though in that it only uses few clinical variables which can be used as a bedside assessment tool and does not need specialist preknowledge of other subscales and classifications.
Back in 2001, Counsell's systematic review commented on the overall poor quality and lack of improvement in stroke prognosis research over a time period of two decades. (7) In comparison to Counsell's findings, our updated systematic review of studies published in the last ten years has identified larger, more rigorous studies that may have been previously lacking. Unlike the previous systematic review, we were able to carry out meta-analysis that reported appropriate statistical measures from a variety of validation sets. We believe that the information from our systematic review will be very useful in helping researchers stratify and match patients when comparing mortality outcomes in observational studies of stroke care (e.g. between different healthcare centres, or different times of presentation such as weekends or weekdays).
However, the available studies do not report on acceptability and uptake of current prognostic scores in the day to day management of stroke patients. While good performance of a prediction rule is an important pre-requisite, patients will not gain any benefits from the profusion of prognostic scoring models if the uptake and implementation is patchy. There are parallels here with prognostic indices in community-acquired pneumonia, where an Australian survey found that only 12% of respiratory physicians and 35% emergency physicians reported regular use of the highly sensitive Pneumonia Severity Index. (29) The complexity of calculation proved challenging and many physicians were unable to accurately estimate the Pneumonia Severity Index scores. (29) Ideally, a prognostic score should be easy to use (without requiring specialist training or additional steps in having to calculate a subscale beforehand), memorable and accurate.
Our systematic review has limitations. We have focused only on research carried out over the last ten years and we chose not to emphasize functional outcomes because they are assessed in diverse ways, and determined to some extent by pre-stroke status. We aimed to specifically evaluate overall mortality as a hard outcome, bearing in mind findings from a recent systematic review where existing prognostic models in stroke had poor discriminant ability for recurrent stroke and myocardial infarction. (30) The majority of our included studies were retrospective, or posthoc analyses of prospectively collected clinical data and we have not categorized studies into either high or low quality subgroups. We selected published studies which used the AUC or cstatistic as their primary measure; it is possible that studies that found poor discriminant ability may have been unpublished or unreported. The aetiology and severity of stroke can vary considerably across different geographical and ethnic populations, and a model that performs well in one hospital may perform less accurately in another setting without further re-calibration.
We appreciate that prognostic models are imperfect, and should only be interpreted together with clinical information and judgment.
Conclusions
There are now a number of stroke prognostic scores showing moderate to good performance in predicting mortality after ischaemic stroke, and our review suggests that the iSCORE has the broadest supporting evidence base amongst the available prognostic tools.
We feel that the most promising recently validated models should all be compared directly in a large, prospective multi-centre international cohort measuring clinician uptake and ensuring treatment on the same pathway.
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